Does Semaglutide Make You Less Hungry?

What is semaglutide actually doing to your appetite signals?

Semaglutide is a GLP-1 receptor agonist, it mimics a hormone your gut naturally releases after eating. One of that hormone's jobs is to travel to the hypothalamus and dial down the "eat more" signal. Semaglutide does this for a sustained period rather than the few minutes a natural GLP-1 pulse lasts, which is why the appetite effect carries across the whole week between injections.

There are two routes through which this plays out. First, the brain side: reduced hunger signals mean you think about food less, feel less urgent about meals, and find it easier to stop eating sooner. Second, the gut side: semaglutide slows gastric emptying, so the physical sensation of fullness after a meal lasts longer than it would otherwise. Neither route requires you to consciously override an urge. The biology is doing something different before the urge fully forms.

This is a question our prescribers hear most weeks, usually from people who are sceptical that a medicine could genuinely reduce appetite rather than just help them resist it. The honest answer is that for the majority of people who use Wegovy, the change is noticeable, though not uniform. Some describe it as their internal food-noise dropping to a manageable level. Others say portions simply feel adequate where they used to feel insufficient.

For a deeper look at how the fullness effect specifically plays out, our page on whether Wegovy makes you eat less covers the practical side in more detail.

Does the hunger reduction stay consistent, or does it fade over time?

The appetite effect is often most noticeable in the first few weeks of treatment and in the days following a dose increase. As your body adjusts to each new dose level, some of that acute reduction can settle, though for most people a meaningful background reduction in hunger persists throughout treatment.

The titration schedule for Wegovy, which starts at 0.25 mg and steps up over several months toward the 2.4 mg maintenance dose, is designed partly with this in mind. Starting low reduces the chance of significant nausea, but it also means the full appetite effect tends to build gradually rather than hitting all at once. At maintenance dose, the sustained reduction in appetite is what drives the longer-term weight changes seen in trials like STEP 1, published in the New England Journal of Medicine, where average weight loss reached around 15% over 68 weeks.

There is a small subset of people who find the hunger-reducing effect less marked than expected, or who notice it returns more strongly between doses. If you are curious about that pattern, our page on why semaglutide can sometimes increase hunger covers the less-discussed side of this question. And if you want to understand the broader picture of appetite variation across the dose journey, the page on semaglutide and hunger explores that in full.

Appetite is one variable. What you eat while it's reduced still matters, protein intake, fibre, and hydration all influence how well the appetite effect supports actual weight management. Our guide on what to eat on Wegovy covers the practical nutrition side.

Is the hunger effect the same with the Wegovy tablet as with the injection?

Wegovy is available in two licensed UK forms: the weekly injection and, as of June 2026, the once-daily tablet. Both deliver semaglutide, the mechanism of action, and therefore the appetite-related effects, is the same. The tablet reaches its maintenance dose of 25 mg after a gradual escalation from 1.5 mg, taken first thing in the morning on an empty stomach.

The appetite-reduction evidence for the tablet comes from the OASIS 4 trial, which showed an average weight loss of around 13.6% over 64 weeks alongside lifestyle changes. Among participants who stayed fully adherent to treatment, that figure was closer to 17%. Both figures reflect sustained appetite suppression as the primary driver, participants were eating less because they genuinely wanted to, not because they were forcing restraint.

If you are weighing up whether the injection or tablet suits your life better, our Wegovy overview page sets out the differences clearly, including the storage and dosing practicalities that vary between the two forms. The free consultation is where a prescriber can help you work out which option fits your circumstances, if semaglutide is clinically suitable for you.

When appetite reduction is less than expected, what else might be happening?

Not everyone experiences a dramatic drop in hunger, and that is worth saying plainly rather than glossing over. A few things can influence how much the appetite effect comes through. Eating very quickly, choosing calorie-dense foods that are easy to overconsume regardless of satiety signals, or being in a period of high psychological stress can all partly override what the medicine is doing physiologically.

There is also the question of what happens if semaglutide is not quite the right fit. Tirzepatide, the active ingredient in Mounjaro, works across two receptor pathways rather than one (GIP as well as GLP-1) and some people find the appetite and fullness effect more pronounced with that dual mechanism. The head-to-head SURMOUNT-5 trial found greater average weight loss with tirzepatide compared to semaglutide 2.4 mg, though which medicine suits any individual is always a clinical decision. Our weight loss treatments overview covers both options without steering you toward one before you've spoken to a prescriber.

If you are already on semaglutide and finding hunger returning in ways you didn't expect, the page on increased hunger on semaglutide (and separately the one on how completely Wegovy suppresses appetite) address those more specific situations. For meal-planning that works alongside any GLP-1 treatment, the semaglutide meal plan guide is a practical starting point.